跳到正文
原文
Nature 健康护理主题·· 2026-10-07AI 评分52

Nature综述:针对RNA病毒更广谱直接抗病毒药物研发进展

Towards broader-spectrum direct-acting antivirals against RNA viruses

AI 导读

Nature综述探讨了针对RNA病毒更广泛直接抗病毒药物(DAV)的研发。文章指出单一病原体药物易因病毒变异失效,因此研发覆盖多病毒家族的广谱药物是流行病和突发疫情应对的关键。

正文
  1. Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Chumakov, K., Ehrenfeld, E., Agol, V. I. & Wimmer, E. Polio eradication at the crossroads. Lancet Glob. Health 9, e1172–e1175 (2021).

    CAS  PubMed  Google Scholar 

  3. Pattyn, J. et al. Overview of vaccines for adults authorized, recommended, and implemented in the European Union. npj Vaccines 10, 183 (2025).

    Article  PubMed  Google Scholar 

  4. Tannock, G. A., Kim, H. & Xue, L. Why are vaccines against many human viral diseases still unavailable; an historic perspective? J. Med. Virol. 92, 129–138 (2020).

    PubMed  Google Scholar 

  5. Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023).

    Article  CAS  PubMed  Google Scholar 

  6. Kulkarni, P. S. et al. Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial. Lancet 406, 627–635 (2025).

    CAS  PubMed  Google Scholar 

  7. Pecenka, C. et al. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children. Lancet 404, 1157–1170 (2024).

    CAS  PubMed  Google Scholar 

  8. Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162–177 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Toussi, S. S., Hammond, J. L., Gerstenberger, B. S. & Anderson, A. S. Therapeutics for COVID-19. Nat. Microbiol. 8, 771–786 (2023).

    Article  CAS  PubMed  Google Scholar 

  10. Draghia-Akli, R. et al. The indispensable value of small-molecule antivirals in epidemic and pandemic preparedness. Clin. Infect. Dis. 82, e49–e55 (2026).

    PubMed  Google Scholar 

  11. Forni, D., Cagliani, R., Clerici, M. & Sironi, M. Disease-causing human viruses: novelty and legacy. Trends Microbiol. 30, 1232–1242 (2022).

    CAS  PubMed  Google Scholar 

  12. Karim, M., Lo, C.-W. & Einav, S. Preparing for the next viral threat with broad-spectrum antivirals. J. Clin. Invest. 133, e170236 (2023).

    CAS  PubMed  Google Scholar 

  13. Jochmans, D., Laporte, M. & Neyts, J. Antiviral strategies for epidemic and pandemic preparedness. Cell Host Microbe 31, 856–860 (2023).

    CAS  PubMed  Google Scholar 

  14. Qian, B. et al. EIDD-2801 resists to infection and co-infection of SARS-CoV-2 and influenza virus. Virol. J. 22, 126 (2025).

    Article  CAS  PubMed  Google Scholar 

  15. Li, L.-H. et al. Multiplexed multicolor antiviral assay amenable for high-throughput research. Nat. Commun. 15, 42 (2024).

    Article  PubMed  Google Scholar 

  16. von Delft, A. et al. Accelerating antiviral drug discovery: lessons from COVID-19. Nat. Rev. Drug Discov. 22, 585–603 (2023).

    Article  Google Scholar 

  17. Chan, X. et al. Accelerating the clinical development of drugs for dengue: WHO dengue therapeutics landscape analysis and target product profiles. Lancet Microbe 19, 101451 (2027).

    Google Scholar 

  18. Holm-Hansen, C. C., Midgley, S. E. & Fischer, T. K. Global emergence of enterovirus D68: a systematic review. Lancet Infect. Dis. 16, e64–e75 (2016).

    PubMed  Google Scholar 

  19. Jacob, S. T. et al. Ebola virus disease. Nat. Rev. Dis. Primers 6, 13 (2020).

    PubMed  Google Scholar 

  20. Halbrook, M. et al. Mpox in Central Africa: complex epidemiology requires a constellation approach. npj Viruses 2, 69 (2024).

    Article  PubMed  Google Scholar 

  21. Mitjà, O. Andes virus on a cruise ship: person-to-person transmission and an empty pipeline. Lancet Infect. Dis. 26, e271–e272 (2026).

    PubMed  Google Scholar 

  22. Singh, M. & de Wit, E. Antiviral agents for the treatment of COVID-19: progress and challenges. Cell Rep. Med. 3, 100549 (2022).

    CAS  PubMed  Google Scholar 

  23. Hayden, F. G. et al. Ensitrelvir for Covid-19 postexposure prophylaxis in household contacts. N. Engl. J. Med. 394, 1905–1915 (2026).

    CAS  PubMed  Google Scholar 

  24. Mackman, R. L. et al. Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV. J. Med. Chem. 64, 5001–5017 (2021). This paper describes the synthesis and discovery of remdesivir and its therapeutic efficacy against RSV in non-human primates.

    CAS  PubMed  Google Scholar 

  25. Eastman, R. T. et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci. 6, 672–683 (2020).

    CAS  PubMed  Google Scholar 

  26. Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381–385 (2016).

    Article  CAS  PubMed  Google Scholar 

  27. Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017). This paper exemplifies how the antiviral activity of existing drugs could be systematically assessed against viruses with epidemic or pandemic potential.

    PubMed  Google Scholar 

  28. Andersen, P. I. et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int. J. Infect. Dis. 93, 268–276 (2020).

    CAS  PubMed  Google Scholar 

  29. Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41–58 (2019).

    Article  CAS  PubMed  Google Scholar 

  30. Liesenborghs, L. et al. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. eBioMedicine 66, 103288 (2021).

    CAS  PubMed  Google Scholar 

  31. Abdelnabi, R., Maes, P., de Jonghe, S., Weynand, B. & Neyts, J. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. Front. Pharmacol. 13, 1072202 (2022).

    CAS  PubMed  Google Scholar 

  32. Das, K. M. P. Editorial: antiviral drug discovery against pathogens of pandemic concern: advancements in target site identification and structure-based drug development. Front. Mol. Biosci. 10, 1165208 (2023).

    Google Scholar 

  33. Kaptein, S. J. F. et al. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. Nature 598, 504–509 (2021). This paper reports the discovery and molecular mechanism of a first-in-class pan-serotype inhibitor of dengue virus, demonstrating that it blocks the de novo formation of the NS3–NS4B complex.

    Article  CAS  PubMed  Google Scholar 

  34. Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96–100 (2010). This study exemplifies how phenotypic drug discovery can identify potent inhibitors of viral proteins lacking enzymatic activity, leading to the discovery of NS5A inhibitors that now form a cornerstone of combination therapies for hepatitis C virus infection.

    Article  CAS  PubMed  Google Scholar 

  35. Laporte, M. et al. A coronavirus assembly inhibitor that targets the viral membrane protein. Nature 640, 514–523 (2025). Discovery of coronavirus assembly as a druggable target by blocking M- protein oligomerization and subsequent membrane curvature.

    Article  CAS  PubMed  Google Scholar 

  36. Blázquez, A.-B. et al. Lipid-targeting antiviral strategies: current state and future perspectives. Antivir. Res. 236, 106103 (2025).

    PubMed  Google Scholar 

  37. Krasilnikov, M. S., Denisov, V. S., Korshun, V. A., Ustinov, A. V. & Alferova, V. A. Membrane-targeting antivirals. Int. J. Mol. Sci. 26, 7276 (2025).

    CAS  PubMed  Google Scholar 

  38. Dsouza, L. & Yang, Z. Viral reprogramming of nucleotide synthesis and its impact on viral infection. J. Med. Virol. 97, e70563 (2025).

    CAS  PubMed  Google Scholar 

  39. Tian, L. et al. RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic. Eur. J. Med. Chem. 213, 113201 (2021).

    CAS  PubMed  Google Scholar 

  40. Charon, J., Buchmann, J. P., Sadiq, S. & Holmes, E. C. RdRp-scan: a bioinformatic resource to identify and annotate divergent RNA viruses in metagenomic sequence data. Virus Evol. 8, veac082 (2022).

    PubMed  Google Scholar 

  41. Jia, H. & Gong, P. A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses. Front. Microbiol. 10, 1945 (2019).

    PubMed  Google Scholar 

  42. te Velthuis, A. J. W. Common and unique features of viral RNA-dependent polymerases. Cell. Mol. Life Sci. 71, 4403–4420 (2014). Key review (together with reference 33) that summarizes shared and distinct features of viral RNA polymerases.

    Article  Google Scholar 

  43. Ferrero, D., Ferrer-Orta, C. & Verdaguer, N. Viral RNA-dependent RNA polymerases: a structural overview. In Virus Protein and Nucleoprotein Complexes (eds Harris, J. R. & Bhella, D.) 39–71 (Springer, 2018).

  44. Hillen, H. S. et al. Structure of replicating SARS-CoV-2 polymerase. Nature 584, 154–156 (2020).

    Article  CAS  PubMed  Google Scholar 

  45. Te Velthuis, A. J. W., Grimes, J. M. & Fodor, E. Structural insights into RNA polymerases of negative-sense RNA viruses. Nat. Rev. Microbiol. 19, 303–318 (2021).

    Article  Google Scholar 

  46. Ramaswamy, K., Rashid, M., Ramasamy, S., Jayavelu, T. & Venkataraman, S. Revisiting viral RNA-dependent RNA polymerases: insights from recent structural studies. Viruses 14, 2200 (2022).

    CAS  PubMed  Google Scholar 

  47. Huchting, J. Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections. Antivir. Chem. Chemother. 28, 2040206620976786 (2020).

    CAS  PubMed  Google Scholar 

  48. Palazzotti, D. et al. Small molecule drugs targeting viral polymerases. Pharmaceuticals 17, 661 (2024).

    CAS  PubMed  Google Scholar 

  49. Mehellou, Y., Rattan, H. S. & Balzarini, J. The protide prodrug technology: from the concept to the clinic. J. Med. Chem. 61, 2211–2226 (2018).

    CAS  PubMed  Google Scholar 

  50. Shannon, A. & Canard, B. Kill or corrupt: mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2. Antivir. Res. 210, 105501 (2023).

    CAS  PubMed  Google Scholar 

  51. Gordon, C. J., Tchesnokov, E. P., Schinazi, R. F. & Götte, M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 297, 100770 (2021).

    CAS  PubMed  Google Scholar 

  52. Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740–746 (2021).

    Article  CAS  PubMed  Google Scholar 

  53. Kaptein, S. J. F. et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl Acad. Sci. USA 117, 26955–26965 (2020).

    CAS  PubMed  Google Scholar 

  54. Sofia, M. J. et al. Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202–7218 (2010).

    CAS  PubMed  Google Scholar 

  55. Lam, A. M. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56, 3359–3368 (2012).

    CAS  PubMed  Google Scholar 

  56. Cornberg, M. et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - the HepNet SofE pilot study. J. Hepatol. 73, 696–699 (2020).

    CAS  PubMed  Google Scholar 

  57. Ferreira, A. C. et al. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrob. Agents Chemother. 63, e01389-18 (2019).

    PubMed  Google Scholar 

  58. Medina, A. et al. Treatment with sofosbuvir attenuates the adverse neurodevelopmental consequences of Zika virus infection in infant rhesus macaques. J. Neuroimmunol. 381, 578148 (2023).

    CAS  PubMed  Google Scholar 

  59. Rubin, D., Chan-Tack, K., Farley, J. & Sherwat, A. FDA approval of remdesivir — a step in the right direction. N. Engl. J. Med. 383, 2598–2600 (2020).

    CAS  PubMed  Google Scholar 

  60. Mackman, R. L. Phosphoramidate prodrugs continue to deliver, the journey of remdesivir (GS-5734) from RSV to SARS-CoV-2. ACS Med. Chem. Lett. 13, 338–347 (2022).

    CAS  PubMed  Google Scholar 

  61. Lin, Y. et al. A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology. Nat. Commun. 15, 7765 (2024).

    Article  CAS  PubMed  Google Scholar 

  62. Lo, M. K. et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 11, eaau9242 (2019).

    CAS  PubMed  Google Scholar 

  63. Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 169, 104541 (2019).

    CAS  PubMed  Google Scholar 

  64. Radoshitzky, S. R. et al. Expanded profiling of remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci. Rep. 13, 3131 (2023).

    Article  CAS  PubMed  Google Scholar 

  65. Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci. Rep. 7, 43395 (2017).

    Article  PubMed  Google Scholar 

  66. Ueda, M., Tanimoto, T., Murayama, A., Ozaki, A. & Kami, M. Japan’s drug regulation during the COVID-19 pandemic: lessons from a case study of favipiravir. Clin. Pharmacol. Ther. 111, 545–547 (2022).

    CAS  PubMed  Google Scholar 

  67. Shiraki, K. & Daikoku, T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 209, 107512 (2020).

    CAS  PubMed  Google Scholar 

  68. Hayden, F. G. et al. Favipiravir treatment of uncomplicated influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials. J. Infect. Dis. 226, 1790–1799 (2022).

    CAS  PubMed  Google Scholar 

  69. Delang, L., Abdelnabi, R. & Neyts, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir. Res. 153, 85–94 (2018).

    CAS  PubMed  Google Scholar 

  70. Erameh, C. et al. Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial. Nat. Med. 32, 2522–2532 (2026).

    Article  CAS  PubMed  Google Scholar 

  71. Lee, J. S. et al. Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. BMC Infect. Dis. 19, 376 (2019).

    Article  PubMed  Google Scholar 

  72. Batool, S. et al. Efficacy and safety of favipiravir in treating COVID-19 patients: a meta-analysis of randomized control trials. Cureus 15, e33676 (2023).

    PubMed  Google Scholar 

  73. Zhou, S. et al. β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 224, 415–419 (2021).

    CAS  PubMed  Google Scholar 

  74. Toots, M. et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 11, eaax5866 (2019). This paper describes the discovery of molnupiravir as a potent and bioavailable RdRp inhibitor of influenza A and B viruses.

    CAS  PubMed  Google Scholar 

  75. Yoon, J.-J. et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 62, e00766-18 (2018).

    PubMed  Google Scholar 

  76. Painter, G. R. et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection. Antivir. Res. 171, 104597 (2019).

    CAS  PubMed  Google Scholar 

  77. Wang, Z. et al. In vitro and in vivo efficacy of molnupiravir against Zika virus infections. Virol. Sin. 38, 639–642 (2023).

    CAS  PubMed  Google Scholar 

  78. Painter, G. R., Natchus, M. G., Cohen, O., Holman, W. & Painter, W. P. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr. Opin. Virol. 50, 17–22 (2021).

    CAS  PubMed  Google Scholar 

  79. Santos-Ferreira, N. et al. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids. Antivir. Res. 223, 105839 (2024).

    CAS  PubMed  Google Scholar 

  80. Stuyver, L. J. et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother. 47, 244–254 (2003).

    CAS  PubMed  Google Scholar 

  81. Bluemling, G. R. et al. The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N4-hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antivir. Res. 209, 105453 (2023).

    CAS  PubMed  Google Scholar 

  82. Wang, Q. et al. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 199, 105273 (2022).

    CAS  PubMed  Google Scholar 

  83. Sanderson, T. et al. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature 623, 594–600 (2023).

    Article  CAS  PubMed  Google Scholar 

  84. Warren, T. K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402–405 (2014).

    Article  CAS  PubMed  Google Scholar 

  85. Julander, J. G. et al. An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. Antivir. Res. 195, 105180 (2021).

    CAS  PubMed  Google Scholar 

  86. Shannon, A. et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat. Commun. 13, 621 (2022).

    Article  CAS  PubMed  Google Scholar 

  87. Zhou, X.-J. et al. In vitro and clinical evaluation of potential interactions of bemnifosbuvir with drug-metabolizing enzymes. J. Clin. Pharmacol. 66, e70170 (2026).

    CAS  PubMed  Google Scholar 

  88. Berliba, E. et al. Safety, pharmacokinetics, and antiviral activity of AT-527, a novel purine nucleotide prodrug, in hepatitis C virus-infected subjects with or without cirrhosis. Antimicrob. Agents Chemother. https://doi.org/10.1128/aac.01201-19 (2019).

    Article  PubMed  Google Scholar 

  89. Good, S. S., Moussa, A., Zhou, X.-J., Pietropaolo, K. & Sommadossi, J.-P. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS ONE 15, e0227104 (2020).

    CAS  PubMed  Google Scholar 

  90. Hu, J. et al. Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models. Gut https://doi.org/10.1136/gutjnl-2025-336714 (2026).

    Article  PubMed  Google Scholar 

  91. Good, S. S. et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob. Agents Chemother. https://doi.org/10.1128/aac.02479-20 (2021).

    Article  PubMed  Google Scholar 

  92. Sourimant, J. et al. 4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science 375, 161–167 (2022). This paper describes the discovery of 4′-fluorouridine as an inhibitor of the RdRp of RSV, several members of the Paramyxoviridae family and SARS-CoV-2.

    CAS  PubMed  Google Scholar 

  93. Schrell, L. et al. Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine. Antivir. Res. 233, 106046 (2025).

    CAS  PubMed  Google Scholar 

  94. Welch, S. R. et al. Delayed low-dose oral administration of 4′-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease. Sci. Transl. Med. 16, eado7034 (2024).

    CAS  PubMed  Google Scholar 

  95. Escaffre, O. et al. Efficacy of the nucleoside analog 4′-fluorouridine against Nipah virus in the Syrian hamster model. PLoS Pathog. 22, e1014093 (2026).

    CAS  PubMed  Google Scholar 

  96. Lieber, C. M. et al. 4’-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses. PLOS Pathog. 19, e1011342 (2023).

    CAS  PubMed  Google Scholar 

  97. Yin, P. et al. 4′-Fluorouridine inhibits alphavirus replication and infection in vitro and in vivo. mBio 15, e00420-24 (2024).

    PubMed  Google Scholar 

  98. Wong, J. et al. Impact of mutations affecting 4′-fluorouridine susceptibility on fitness and treatment outcomes for Venezuelan equine encephalitis virus. J. Virol. 100, e0154125 (2026).

    PubMed  Google Scholar 

  99. Sandmann, L. From HCV to HEV: repurposing a nucleoside analogue for hepatitis E therapy. J. Hepatol. 83, 989–991 (2025).

    CAS  PubMed  Google Scholar 

  100. Zhang, X. et al. A pangenotypic hepatitis E virus replication inhibitor with high potency in a rat infection model. Gastroenterology 168, 769–783.e12 (2025).

    CAS  PubMed  Google Scholar 

  101. Wang, G. et al. Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-O-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J. Med. Chem. 58, 1862–1878 (2015).

    CAS  PubMed  Google Scholar 

  102. Deval, J. et al. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2′-fluoro-4′-chloromethyl-cytidine triphosphate. PLoS Pathog. 11, e1004995 (2015).

    PubMed  Google Scholar 

  103. DeVincenzo, J. P. et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N. Engl. J. Med. 373, 2048–2058 (2015).

    CAS  PubMed  Google Scholar 

  104. Lo, M. K. et al. Potent in vitro activity of β-D-4′-chloromethyl-2′-deoxy-2′-fluorocytidine against Nipah virus. Antivir. Res. 175, 104712 (2020).

    CAS  PubMed  Google Scholar 

  105. Pierra, C. et al. Nm 283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 24, 767–770 (2005).

    CAS  PubMed  Google Scholar 

  106. Pierra, C. et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J. Med. Chem. 49, 6614–6620 (2006).

    CAS  PubMed  Google Scholar 

  107. Lee, J.-C. et al. Characterization of the activity of 2′-C-methylcytidine against dengue virus replication. Antivir. Res. 116, 1–9 (2015).

    CAS  PubMed  Google Scholar 

  108. Rocha-Pereira, J. et al. Inhibition of norovirus replication by the nucleoside analogue 2′-C-methylcytidine. Biochem. Biophys. Res. Commun. 427, 796–800 (2012).

    CAS  PubMed  Google Scholar 

  109. Van Dycke, J. et al. A single nucleoside viral polymerase inhibitor against norovirus, rotavirus, and sapovirus-induced diarrhea. J. Infect. Dis. 218, 1753–1758 (2018).

    PubMed  Google Scholar 

  110. Amblard, F. et al. 1′-Cyanocytidine-5′-isobutyryl is a potent SARS-CoV-2 inhibitor in culture and infected Syrian hamsters. Sci. Adv. 11, eadz5913 (2025).

    CAS  PubMed  Google Scholar 

  111. Luo, H., Ran, T., Wang, L. & Chen, H. NA-DB: an online database of nucleoside analogues. J. Chem. Inf. Model. 65, 5255–5272 (2025).

    CAS  PubMed  Google Scholar 

  112. Cox, R. M. et al. Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nat. Microbiol. 5, 1232–1246 (2020). This work demonstrates that conserved allosteric sites on the paramyxovirus RdRp can be exploited to achieve orally active, broader-spectrum antiviral inhibition.

    Article  CAS  PubMed  Google Scholar 

  113. Lieber, C. M. et al. Developmental candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models. Sci. Adv. 12, eaef1594 (2026).

    CAS  PubMed  Google Scholar 

  114. Kleiner, V. A. et al. Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerases. Commun. Biol. 6, 649 (2023).

    Article  CAS  PubMed  Google Scholar 

  115. Yi, D. et al. Identification of a broad-spectrum viral inhibitor targeting a novel allosteric site in the RNA-dependent RNA polymerases of dengue virus and norovirus. Front. Microbiol. 11, 1440 (2020).

    PubMed  Google Scholar 

  116. Ghosh, A. K., Osswald, H. L. & Prato, G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med. Chem. 59, 5172–5208 (2016).

    CAS  PubMed  Google Scholar 

  117. Zephyr, J., Kurt Yilmaz, N. & Schiffer, C. A. Viral proteases: structure, mechanism and inhibition. Enzymes 50, 301–333 (2021).

    CAS  PubMed  Google Scholar 

  118. Altman, M. D. et al. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J. Am. Chem. Soc. 130, 6099–6113 (2008).

    CAS  PubMed  Google Scholar 

  119. Martino, S. D., Petri, G. L. & De Rosa, M. Hepatitis C: the story of a long journey through first, second, and third generation NS3/4A peptidomimetic inhibitors. What did we learn? J. Med. Chem. 67, 885–921 (2024).

    CAS  PubMed  Google Scholar 

  120. Boike, L., Henning, N. J. & Nomura, D. K. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 21, 881–898 (2022).

    Article  CAS  PubMed  Google Scholar 

  121. Aljoundi, A., Bjij, I., El Rashedy, A. & Soliman, M. E. S. Covalent versus non-covalent enzyme inhibition: which route should we take? A justification of the good and bad from molecular modelling perspective. Protein J. 39, 97–105 (2020).

    Article  CAS  PubMed  Google Scholar 

  122. Phoo, W. W. et al. Crystal structures of full length DENV4 NS2B-NS3 reveal the dynamic interaction between NS2B and NS3. Antivir. Res. 182, 104900 (2020).

    CAS  PubMed  Google Scholar 

  123. Voss, S., Rademann, J. & Nitsche, C. Characterisation of ten NS2B-NS3 proteases: paving the way for pan-flavivirus drugs. Antivir. Res. 226, 105878 (2024).

    CAS  PubMed  Google Scholar 

  124. Nitsche, C. Proteases from dengue, West Nile and Zika viruses as drug targets. Biophys. Rev. 11, 157–165 (2019).

    Article  CAS  PubMed  Google Scholar 

  125. Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586–1593 (2021). This paper describes the discovery and characterization of the protease inhibitor nirmatrelvir, highlighting how previous knowledge facilitated rapid drug development during the SARS-CoV-2 pandemic.

    CAS  PubMed  Google Scholar 

  126. Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499–6512 (2022).

    CAS  PubMed  Google Scholar 

  127. Li, J. et al. Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses. Antivir. Res. 211, 105555 (2023).

    CAS  PubMed  Google Scholar 

  128. Krismer, L. et al. Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir. npj Viruses 2, 23 (2024).

    Article  CAS  PubMed  Google Scholar 

  129. Baniecki, M. L. et al. Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19. eBioMedicine 118, 105819 (2025).

    CAS  PubMed  Google Scholar 

  130. Inoue, A. et al. M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings. Antivir. Res. 236, 106118 (2025).

    CAS  PubMed  Google Scholar 

  131. Allerton, C. M. N. et al. A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19. J. Med. Chem. 67, 13550–13571 (2024).

    CAS  PubMed  Google Scholar 

  132. Janin, Y. L. On the origins of SARS-CoV-2 main protease inhibitors. RSC Med. Chem. 15, 81–118 (2024).

    CAS  PubMed  Google Scholar 

  133. Loos, N. H. C., Beijnen, J. H. & Schinkel, A. H. The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism? Int. J. Mol. Sci. 23, 9866 (2022).

    CAS  PubMed  Google Scholar 

  134. Luan, B., Huynh, T., Cheng, X., Lan, G. & Wang, H.-R. Targeting proteases for treating COVID-19. J. Proteome Res. 19, 4316–4326 (2020).

    CAS  PubMed  Google Scholar 

  135. Chang, K.-O., Kim, Y., Lovell, S., Rathnayake, A. D. & Groutas, W. C. Antiviral drug discovery: norovirus proteases and development of inhibitors. Viruses 11, 197 (2019).

    CAS  PubMed  Google Scholar 

  136. Steuber, H. & Hilgenfeld, R. Recent advances in targeting viral proteases for the discovery of novel antivirals. Curr. Top. Med. Chem. 10, 323–345 (2010).

    CAS  PubMed  Google Scholar 

  137. Dai, W. et al. Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2. J. Med. Chem. 65, 2794–2808 (2022).

    CAS  PubMed  Google Scholar 

  138. Bafna, K., Cioffi, C. L., Krug, R. M. & Montelione, G. T. Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals. Front. Chem. 10, 948553 (2022).

    CAS  PubMed  Google Scholar 

  139. Rocha-Pereira, J. et al. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrob. Agents Chemother. 58, 4675–4681 (2014).

    CAS  PubMed  Google Scholar 

  140. Metibemu, D. S., Adeyinka, O. S., Falode, J., Crown, O. & Ogungbe, I. V. Inhibitors of the structural and nonstructural proteins of alphaviruses. ACS Infect. Dis. 10, 2507–2524 (2024).

    CAS  PubMed  Google Scholar 

  141. Sears, J. D. et al. Novel computational pipeline to identify target sites for broad spectrum antiviral drugs. Antivir. Res. 245, 106322 (2026).

    CAS  PubMed  Google Scholar 

  142. Fieulaine, S., Tubiana, T. & Bressanelli, S. De novo modelling of HEV replication polyprotein: five-domain breakdown and involvement of flexibility in functional regulation. Virology 578, 128–140 (2023).

    CAS  PubMed  Google Scholar 

  143. Noshi, T. et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antivir. Res. 160, 109–117 (2018).

    CAS  PubMed  Google Scholar 

  144. ter Horst, S., Conceição-Neto, N., Neyts, J. & Rocha-Pereira, J. Structural and functional similarities in bunyaviruses: perspectives for pan-bunya antivirals. Rev. Med. Virol. 29, e2039 (2019).

    PubMed  Google Scholar 

  145. Todd, B., Tchesnokov, E. P. & Götte, M. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor. J. Biol. Chem. 296, 100486 (2021). This paper identifies and characterizes baloxavir as an endonuclease inhibitor of influenza virus, validating the polymerase PA subunit as a clinically relevant antiviral target.

    CAS  PubMed  Google Scholar 

  146. Olschewski, S., Cusack, S. & Rosenthal, M. The cap-snatching mechanism of bunyaviruses. Trends Microbiol. 28, 293–303 (2020). This review focuses on the cap-snatching mechanism of bunyaviruses with a particular focus on recent structural and mechanistic data.

    CAS  PubMed  Google Scholar 

  147. Omoto, S. et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 8, 9633 (2018).

    Article  PubMed  Google Scholar 

  148. Mullard, A. FDA approves first new flu drug in 20 years. Nat. Rev. Drug Discov. 17, 853–853 (2018).

    Article  PubMed  Google Scholar 

  149. Ter Horst, S. et al. Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin. J. Antimicrob. Chemother. 75, 3189–3193 (2020).

    PubMed  Google Scholar 

  150. Toba, S. et al. Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses. Proc. Natl Acad. Sci. USA 119, e2206104119 (2022).

    CAS  PubMed  Google Scholar 

  151. Konishi, K. et al. A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection. Antimicrob. Agents Chemother. 69, e00186-25 (2025).

    PubMed  Google Scholar 

  152. Reguera, J. et al. Comparative structural and functional analysis of bunyavirus and arenavirus cap-snatching endonucleases. PLoS Pathog. 12, e1005636 (2016).

    PubMed  Google Scholar 

  153. Clark, M. P. et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J. Med. Chem. 57, 6668–6678 (2014).

    CAS  PubMed  Google Scholar 

  154. Leopold, L. et al. Efficacy and safety of pimodivir combined with standard of care in hospitalized and nonhospitalized high-risk adolescents and adults with influenza A infection. J. Infect. Dis. 231, e132–e143 (2025).

    CAS  PubMed  Google Scholar 

  155. Byrn, R. A. et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob. Agents Chemother. 59, 1569–1582 (2015).

    PubMed  Google Scholar 

  156. Ferron, F., Decroly, E., Selisko, B. & Canard, B. The viral RNA capping machinery as a target for antiviral drugs. Antivir. Res. 96, 21–31 (2012).

    CAS  PubMed  Google Scholar 

  157. Decroly, E., Ferron, F., Lescar, J. & Canard, B. Conventional and unconventional mechanisms for capping viral mRNA. Nat. Rev. Microbiol. 10, 51–65 (2012).

    Article  CAS  Google Scholar 

  158. Yan, L. et al. Structural basis for the concurrence of template recycling and RNA capping in SARS-CoV-2. Cell 188, 7194–7205.e10 (2025).

    CAS  PubMed  Google Scholar 

  159. Luo, M. et al. SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation. Nat. Commun. 16, 9671 (2025).

    Article  PubMed  Google Scholar 

  160. Misra, A. et al. Structural insights into the assembly and regulation of 2′-O RNA methylation by SARS-CoV-2 nsp16/nsp10. Structure 33, 1027–1039.e4 (2025).

    CAS  PubMed  Google Scholar 

  161. Meyer, C. et al. Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase. Nature 637, 1178–1185 (2025).

    Article  CAS  PubMed  Google Scholar 

  162. Delang, L. et al. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci. Rep. 6, 31819 (2016).

    Article  CAS  PubMed  Google Scholar 

  163. Pushparaj, P. & Hedestam, G. B. K. On target: antibodies against the neuraminidase active site. Trends Microbiol. 33, 1252–1253 (2025).

    CAS  PubMed  Google Scholar 

  164. Kumari, R. et al. Antiviral approaches against influenza virus. Clin. Microbiol. Rev. 36, e00040–22 (2023).

    PubMed  Google Scholar 

  165. Kawai, N. et al. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009–2010 season: a comparison with seasonal H1N1 with or without H275Y mutation. J. Infect. Chemother. 18, 180–186 (2012).

    Article  CAS  PubMed  Google Scholar 

  166. Moscona, A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J. Clin. Invest. 115, 1688–1698 (2005).

    CAS  PubMed  Google Scholar 

  167. Pascolutti, M. et al. Structural insights into human parainfluenza virus 3 hemagglutinin–neuraminidase using unsaturated 3-N-substituted sialic acids as probes. ACS Chem. Biol. 13, 1544–1550 (2018).

    CAS  PubMed  Google Scholar 

  168. Lawrence, M. C. et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J. Mol. Biol. 335, 1343–1357 (2004).

    CAS  PubMed  Google Scholar 

  169. Takahashi, T. et al. Novel sialidase inhibitors suppress mumps virus replication and infection. Glycobiology 34, cwae059 (2024).

    CAS  PubMed  Google Scholar 

  170. Alymova, I. V. et al. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo. Antimicrob. Agents Chemother. 48, 1495–1502 (2004).

    CAS  PubMed  Google Scholar 

  171. Kwong, A. D., Rao, B. G. & Jeang, K.-T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 4, 845–853 (2005).

    Article  CAS  PubMed  Google Scholar 

  172. Karpe, Y. A., Aher, P. P. & Lole, K. S. NTPase and 5′-RNA triphosphatase activities of chikungunya virus nsP2 protein. PLoS ONE 6, e22336 (2011).

    CAS  PubMed  Google Scholar 

  173. Grimes, S. L. & Denison, M. R. The coronavirus helicase in replication. Virus Res. 346, 199401 (2024).

    CAS  PubMed  Google Scholar 

  174. Jain, R., Coloma, J., García-Sastre, A. & Aggarwal, A. K. Structure of the NS3 helicase from Zika virus. Nat. Struct. Mol. Biol. 23, 752–754 (2016).

    Article  CAS  PubMed  Google Scholar 

  175. Hurdiss, D. L. et al. Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes a ring-shaped hexameric complex. Sci. Adv. 8, eabj7615 (2022).

    CAS  PubMed  Google Scholar 

  176. Li, T.-F. et al. Human norovirus NS3 has RNA helicase and chaperoning activities. J. Virol. 92, e01606-17 (2018).

    PubMed  Google Scholar 

  177. Shu, T. et al. Respiratory syncytial virus phosphoprotein has NTPase and helicase-like activities. J. Virol. 99, e00996-25 (2025).

    PubMed  Google Scholar 

  178. Shu, T. et al. Ebola virus VP35 has novel NTPase and helicase-like activities. Nucleic Acids Res. 47, 5837–5851 (2019).

    CAS  PubMed  Google Scholar 

  179. Yao, Q. et al. Structural and mechanistic insights into herpesvirus helicase–primase and its therapeutic inhibitors. Nat. Microbiol. 10, 3191–3201 (2025).

    Article  CAS  PubMed  Google Scholar 

  180. Li, K. et al. A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis. Nat. Commun. 16, 5987 (2025). This study reports the rational design of a 2C helicase inhibitor with in vivo efficacy and broad activity across multiple enteroviruses, validating 2C as a target for pan-enterovirus antiviral development.

    Article  CAS  PubMed  Google Scholar 

  181. Sarvari, G. & Boehr, D. D. Structure, function and inhibition of helicases involved in virus infection. Biomolecules 16, 273 (2026).

    CAS  PubMed  Google Scholar 

  182. Durbin, A. P. et al. Daily mosnodenvir as dengue prophylaxis in a controlled human infection model. N. Engl. J. Med. 393, 2107–2118 (2025). This study describes clinical data on mosnodenvir, demonstrating efficacy in a controlled human infection model, further validating NS3–NS4B as a druggable target.

    CAS  PubMed  Google Scholar 

  183. Moquin, S. A. et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci. Transl. Med. 13, eabb2181 (2021).

    CAS  PubMed  Google Scholar 

  184. Guo, F. et al. A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein. J. Virol. 90, 10774–10788 (2016).

    CAS  PubMed  Google Scholar 

  185. Pang, S. et al. Drug discovery of antiviral inhibitors targeting dengue virus NS4B protein. ACS Infect. Dis. 12, 1555–1571 (2026).

    CAS  PubMed  Google Scholar 

  186. Baggen, J., Thibaut, H. J., Strating, J. R. P. M. & van Kuppeveld, F. J. M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 16, 368–381 (2018).

    Article  CAS  PubMed  Google Scholar 

  187. Larson, R. A. et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82, 10768–10775 (2008).

    CAS  PubMed  Google Scholar 

  188. Katz, M. et al. pH-induced conformational changes and inhibition of the Lassa virus spike complex. Cell Host Microbe 33, 1577–1588.e7 (2025).

    CAS  PubMed  Google Scholar 

  189. Aggarwal, M. & Plemper, R. K. Structural insight into paramyxovirus and pneumovirus entry inhibition. Viruses 12, 342 (2020).

    CAS  PubMed  Google Scholar 

  190. Rimaux, S. et al. N-[(Thiophen-3-yl)methyl]benzamides as fusion inhibitors of influenza virus targeting H1 and H5 hemagglutinins. J. Med. Chem. 68, 18491–18518 (2025).

    CAS  PubMed  Google Scholar 

  191. Chen, Z., Cui, Q., Caffrey, M., Rong, L. & Du, R. Small molecule inhibitors of influenza virus entry. Pharmaceuticals 14, 587 (2021).

    PubMed  Google Scholar 

  192. Ezzatpour, S. et al. Broad-spectrum synthetic carbohydrate receptors (SCRs) inhibit viral entry across multiple virus families. Sci. Adv. 11, eady3554 (2025).

    CAS  PubMed  Google Scholar 

  193. Mathez, G. et al. A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo. Sci. Adv. 11, eadv9311 (2025).

    CAS  PubMed  Google Scholar 

  194. Canales, E. et al. Discovery of lenacapavir: first-in-class twice-yearly capsid inhibitor for HIV-1 treatment and pre-exposure prophylaxis. J. Med. Chem. 68, 21072–21094 (2025).

    CAS  PubMed  Google Scholar 

  195. Van Damme, E. et al. A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein. Nature 640, 506–513 (2025).

    Article  PubMed  Google Scholar 

  196. Norris, M. J. et al. Measles and Nipah virus assembly: specific lipid binding drives matrix polymerization. Sci. Adv. 8, eabn1440 (2022).

    CAS  PubMed  Google Scholar 

  197. Miao, M., De Clercq, E. & Li, G. Clinical significance of chemokine receptor antagonists. Expert Opin. Drug Metab. Toxicol. 16, 11–30 (2020).

    PubMed  Google Scholar 

  198. Manns, M. P. & Maasoumy, B. Breakthroughs in hepatitis C research: from discovery to cure. Nat. Rev. Gastroenterol. Hepatol. 19, 533–550 (2022).

    Article  PubMed  Google Scholar 

  199. Orosco, F. Pan-viral efficacy profile of ribavirin: quantitative potency and safety landscape across virus families. Pharmacia 72, 1–11 (2025).

    CAS  Google Scholar 

  200. Beaucourt, S. & Vignuzzi, M. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr. Opin. Virol. 8, 10–15 (2014).

    CAS  PubMed  Google Scholar 

  201. Leyssen, P., Balzarini, J., De Clercq, E. & Neyts, J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79, 1943–1947 (2005).

    CAS  PubMed  Google Scholar 

  202. Rotman, Y. et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 63, 161–169 (2014).

    CAS  PubMed  Google Scholar 

  203. Graci, J. D. & Cameron, C. E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16, 37–48 (2006).

    CAS  PubMed  Google Scholar 

  204. Johnson, S. et al. Ribavirin for treating Crimean Congo haemorrhagic fever. Cochrane Database Syst. Rev. 6, CD012713 (2018).

    PubMed  Google Scholar 

  205. Qiao, W., Xie, X., Shi, P.-Y., Ooi, Y. S. & Carette, J. E. Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses. Proc. Natl Acad. Sci. USA 122, e2421573122 (2025).

    CAS  PubMed  Google Scholar 

  206. Dujardin, M., Bouckaert, J., Rucktooa, P. & Hanoulle, X. X-ray structure of alisporivir in complex with cyclophilin A at 1.5 Å resolution. Acta Crystallogr. F 74, 583–592 (2018).

    CAS  Google Scholar 

  207. Coelmont, L. et al. DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin a induced cis-trans isomerisation in domain II of NS5A. PLoS ONE 5, e13687 (2010).

    PubMed  Google Scholar 

  208. Stanciu, C., Trifan, A., Muzica, C. & Sfarti, C. Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin. Pharmacother. 20, 379–384 (2019).

    CAS  PubMed  Google Scholar 

  209. Martina, M. G. et al. Bithiazole inhibitors of PI4KB show broad-spectrum antiviral activity against different viral families. Antivir. Res. 231, 106003 (2024).

    CAS  PubMed  Google Scholar 

  210. Delang, L. et al. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. J. Antimicrob. Chemother. 73, 3375–3384 (2018).

    CAS  PubMed  Google Scholar 

  211. Zhao, H. et al. Locational and functional characterization of PI4KB in the mouse embryo. J. Cell. Physiol. 239, e31195 (2024).

    CAS  PubMed  Google Scholar 

  212. Spickler, C. et al. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob. Agents Chemother. 57, 3358–3368 (2013).

    CAS  PubMed  Google Scholar 

  213. Phillpotts, R. et al. The activity of enviroxime against rhinovirus infection in man. Lancet 317, 1342–1344 (1981).

    Google Scholar 

  214. van der Linden, L., Wolthers, K. C. & van Kuppeveld, F. J. Replication and inhibitors of enteroviruses and parechoviruses. Viruses 7, 4529–4562 (2015).

    PubMed  Google Scholar 

  215. Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).

    Article  PubMed  Google Scholar 

  216. Montrose, K. & Krissansen, G. W. Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus. Biochem. Biophys. Res. Commun. 453, 735–740 (2014).

    CAS  PubMed  Google Scholar 

  217. de Wispelaere, M. et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 10, 3468 (2019).

    Article  PubMed  Google Scholar 

  218. Alugubelli, Y. R. et al. Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease. J. Med. Chem. 67, 6495–6507 (2024).

    CAS  PubMed  Google Scholar 

  219. Zhao, N. et al. Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics. Cell Host Microbe 31, 1154–1169.e10 (2023).

    CAS  PubMed  Google Scholar 

  220. Newton, L. S. et al. Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV. Nat. Commun. 16, 1484 (2025).

    Article  CAS  PubMed  Google Scholar 

  221. Jin, J. et al. PROTACs in antivirals: current advancements and future perspectives. Molecules 30, 3402 (2025).

    CAS  PubMed  Google Scholar 

  222. Bhole, R. P., Kute, P. & Gurav, S. S. PROTACs in the treatment of viral diseases. Future Med. Chem. 17, 267–269 (2025).

    CAS  PubMed  Google Scholar 

  223. Lv, Z. et al. Targeting SARS-CoV-2 proteases for COVID-19 antiviral development. Front. Chem. 9, 819165 (2022).

    PubMed  Google Scholar 

  224. von Itzstein, M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6, 967–974 (2007).

    Article  Google Scholar 

  225. Zhang, K. et al. Deciphering the enigmas of non-nucleoside reverse transcriptase inhibitors (NNRTIs): a medicinal chemistry expedition towards combating HIV drug resistance. Med. Res. Rev. 45, 426–483 (2025).

    CAS  PubMed  Google Scholar 

  226. Abdelnabi, R. et al. A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol. 17, e3000281 (2019).

    PubMed  Google Scholar 

  227. Chandrasekaran, S. N., Ceulemans, H., Boyd, J. D. & Carpenter, A. E. Image-based profiling for drug discovery: due for a machine-learning upgrade? Nat. Rev. Drug Discov. 20, 145–159 (2021). This review provides an overview on image-based profiling to capture rich, multi-dimensional biological information from biological images and discusses how machine-learning approaches can accelerate drug discovery.

    Article  CAS  PubMed  Google Scholar 

  228. Serrano, E. et al. Progress and new challenges in image-based profiling. Mol. Syst. Biol. 22, 624–658 (2026).

    Article  CAS  PubMed  Google Scholar 

  229. Bray, M.-A. et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat. Protoc. 11, 1757–1774 (2016).

    Article  CAS  PubMed  Google Scholar 

  230. Rietdijk, J. et al. A phenomics approach for antiviral drug discovery. BMC Biol. 19, 156 (2021).

    Article  CAS  PubMed  Google Scholar 

  231. Petkidis, A., Andriasyan, V., Murer, L., Volle, R. & Greber, U. F. A versatile automated pipeline for quantifying virus infectivity by label-free light microscopy and artificial intelligence. Nat. Commun. 15, 5112 (2024).

    Article  CAS  PubMed  Google Scholar 

  232. Bowyer, S., Allen, D. J. & Furnham, N. Unveiling the ghost: machine learning’s impact on the landscape of virology. J. Gen. Virol. 106, 002067 (2025).

    CAS  PubMed  Google Scholar 

  233. Jia, Y. et al. Deep contrastive learning enables genome-wide virtual screening. Science 391, eads9530 (2026). This paper describes DrugCLIP, a virtual genome-wide screening drug discovery tool.

    CAS  PubMed  Google Scholar 

  234. de Vrueh, R. L. A. & Crommelin, D. J. A. Reflections on the future of pharmaceutical public-private partnerships: from input to impact. Pharm. Res. 34, 1985–1999 (2017).

    Article  PubMed  Google Scholar 

  235. de Vrueh, R. L. A., de Vlieger, J. S. B. & Crommelin, D. J. A. Editorial: public-private partnerships as drivers of innovation in healthcare. Front. Med. 6, 114 (2019).

    Google Scholar 

  236. U.S. Department of Health and Human Services Food and Drug Administration. Product Development Under the Animal Rule https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-development-under-animal-rule (FDA, 2015).

  237. Gerke, S., Balamut, J. & Wagner, J. K. The FDA’s plan to phase out animal testing. Trends Biotechnol. 44, 2178–2181 (2026).

    CAS  PubMed  Google Scholar 

  238. Merchlinsky, M. et al. The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antivir. Res. 168, 168–174 (2019).

    CAS  PubMed  Google Scholar 

  239. Ali, R. et al. Tecovirimat for clade I MPXV infection in the Democratic Republic of Congo. N. Engl. J. Med. 392, 1484–1496 (2025). This study describes the limited efficacy of tecovirimat, an antiviral drug approved under the Animal Rule.

    CAS  PubMed  Google Scholar 

  240. Cavaleri, M. et al. Fourth controlled human infection model (CHIM) meeting, CHIM regulatory issues, May 24, 2023. Biologicals 85, 101745 (2024).

    PubMed  Google Scholar 

  241. Hites, M. & Vincent, J.-L. Pharmacological studies in hospitalized COVID-19 patients in Belgium: we could do better. Viruses 14, 1427 (2022).

    CAS  PubMed  Google Scholar 

  242. Goossens, H., Derde, L., Horby, P. & Bonten, M. The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infect. Dis. 22, e153–e158 (2022). This paper provides an overview on lessons learned from the SARS-CoV-2 pandemic and recommends improvements to our response to future outbreaks.

    CAS  PubMed  Google Scholar 

  243. Angus, D. C. et al. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug Discov. 18, 797–807 (2019).

    Article  Google Scholar 

  244. Angeloni, N. A., Adhikari, N. K. & Lamontagne, F. A practical review of adaptive platform trials. Transfus. Med. Rev. 39, 150935 (2025).

    PubMed  Google Scholar 

  245. Callaway, E. Race begins to trial Ebola drugs amid current outbreak. Nature 653, 987–988 (2026).

    Article  CAS  PubMed  Google Scholar 

  246. World Health Organization. Integrating Research into Outbreaks: How Can We Prepare for the Next Marburg Outbreak? https://www.who.int/news-room/events/detail/2023/03/10/default-calendar/who-consultation---integrating-research-into-outbreaks--how-can-we-prepare-for-the-next-marburg-outbreak (WHO, 2023).

  247. Torreele, E. et al. Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better? Lancet Infect. Dis. 23, e253–e258 (2023). This paper describes why effective Ebola treatments, diagnostics and vaccines remain largely inaccessible in affected regions and describes the framework required to make these countermeasures become available where and when they are most needed.

    PubMed  Google Scholar 

来源:Nature 健康护理主题 · nature.com